Literature DB >> 3018537

Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants.

C A Franke, C M Rice, J H Strauss, D E Hruby.   

Abstract

The antibiotic G418 was shown to be an effective inhibitor of vaccinia virus replication when an appropriate concentration of it was added to cell monolayers 48 h before infection. Genetic engineering techniques were used in concert with DNA transfection protocols to construct vaccinia virus recombinants containing the neomycin resistance gene (neo) from transposon Tn5. These recombinants contained the neo gene linked in either the correct or incorrect orientation relative to the vaccinia virus 7.5-kilodalton gene promoter which is expressed constitutively throughout the course of infection. The vaccinia virus recombinant containing the chimeric neo gene in the proper orientation was able to grow and form plaques in the presence of G418, whereas both the wild-type and the recombinant virus with the neo gene in the opposite polarity were inhibited by more than 98%. The effect of G418 on virus growth may be mediated at least in part by selective inhibition of the synthesis of a subset of late viral proteins. These results are discussed with reference to using this system, the conferral of resistance to G418 with neo as a positive selectable marker, to facilitate constructing vaccinia virus recombinants which contain foreign genes of interest.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3018537      PMCID: PMC366908          DOI: 10.1128/mcb.5.8.1918-1924.1985

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  20 in total

1.  Hybridization in situ of SV40 plaques: detection of recombinant SV40 virus carrying specific sequences of nonviral DNA.

Authors:  L P Villarreal; P Berg
Journal:  Science       Date:  1977-04-08       Impact factor: 47.728

2.  Analysis of bacteriophage T7 early RNAs and proteins on slab gels.

Authors:  F W Studier
Journal:  J Mol Biol       Date:  1973-09-15       Impact factor: 5.469

3.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

4.  Restriction enzyme mapping of vaccinia virus DNA.

Authors:  F M DeFilippes
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

5.  Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen.

Authors:  G L Smith; M Mackett; B Moss
Journal:  Nature       Date:  1983-04-07       Impact factor: 49.962

6.  A new selective agent for eukaryotic cloning vectors.

Authors:  J Davies; A Jimenez
Journal:  Am J Trop Med Hyg       Date:  1980-09       Impact factor: 2.345

7.  Vaccinia virus replication requires active participation of the host cell transcriptional apparatus.

Authors:  D E Hruby; D L Lynn; J R Kates
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

8.  Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.

Authors:  E Paoletti; B R Lipinskas; C Samsonoff; S Mercer; D Panicali
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

9.  Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA.

Authors:  J P Weir; G Bajszár; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

10.  Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters.

Authors:  G L Smith; B R Murphy; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

View more
  47 in total

1.  Recombinant vaccinia viruses. Design, generation, and isolation.

Authors:  C C Broder; P L Earl
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

2.  Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env.

Authors:  L Gritz; A Destree; N Cormier; E Day; V Stallard; T Caiazzo; G Mazzara; D Panicali
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

3.  Antithymidylate resistance enables transgene selection and cell survival for T cells in the presence of 5-fluorouracil and antifolates.

Authors:  D Rushworth; A Alpert; R Santana-Carrero; S Olivares; D Spencer; L J N Cooper
Journal:  Gene Ther       Date:  2015-08-14       Impact factor: 5.250

4.  The target DNA sequence for resolution of poxvirus replicative intermediates is an active late promoter.

Authors:  D Stuart; K Graham; M Schreiber; C Macaulay; G McFadden
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

5.  The vaccinia virus gene I2L encodes a membrane protein with an essential role in virion entry.

Authors:  R Jeremy Nichols; Eleni Stanitsa; Bethany Unger; Paula Traktman
Journal:  J Virol       Date:  2008-08-13       Impact factor: 5.103

6.  Utilization of DNA recombination for the two-step replacement of growth factor sequences in the vaccinia virus genome.

Authors:  D D Spyropoulos; V Stallard; B E Roberts; L K Cohen
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

7.  Translational modulation of proteins expressed from bicistronic vectors.

Authors:  Prasun J Mishra; Lata G Menon; Pravin J Mishra; Philipp Mayer-Kuckuk; Joseph R Bertino; Debabrata Banerjee
Journal:  Mol Imaging       Date:  2009-12       Impact factor: 4.488

8.  The 35-kilodalton protein gene (p35) of Autographa californica nuclear polyhedrosis virus and the neomycin resistance gene provide dominant selection of recombinant baculoviruses.

Authors:  R A Lerch; P D Friesen
Journal:  Nucleic Acids Res       Date:  1993-04-25       Impact factor: 16.971

9.  The vaccinia virus G1L putative metalloproteinase is essential for viral replication in vivo.

Authors:  Marika Hedengren-Olcott; Chelsea M Byrd; Jeffrey Watson; Dennis E Hruby
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes.

Authors:  Steven J Conrad; Jia Liu
Journal:  Methods Mol Biol       Date:  2019
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.